Review top news and interview highlights from the week ending May 10, 2024.
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, with a focus on this week's onsite coverage of the 2024 American Society of Gene & Cell Therapy Meeting.
The gene therapy is up for priority review with a PDUFA date of June 21, 2024.
The chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians discussed the phase 1/2 CHORD clinical trial evaluating DB-OTO.
KL003 favorably compares to platelet and neutrophil recovery rates of approved gene therapies.
The research scientist at Seattle Children's Research Institute discussed mouse model research he presented at ASGCT’s 2024 Meeting.
In response to the death, Pfizer is pausing dosing associated with the crossover portion of the phase 3 CIFFREO trial.